- Home
- CNTX vs TLSI Comparison
CNTX vs TLSI Comparison
Compare CNTX & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTX
- TLSI
- Stock Information
- Founded
- CNTX 2015
- TLSI 2010
- Country
- CNTX United States
- TLSI United States
- Employees
- CNTX N/A
- TLSI N/A
- Industry
- CNTX Biotechnology: Pharmaceutical Preparations
- TLSI Medical Specialities
- Sector
- CNTX Health Care
- TLSI Health Care
- Exchange
- CNTX Nasdaq
- TLSI Nasdaq
- Market Cap
- CNTX 149.6M
- TLSI 124.9M
- IPO Year
- CNTX 2021
- TLSI N/A
- Fundamental
- Price
- CNTX $1.30
- TLSI $4.33
- Analyst Decision
- CNTX Strong Buy
- TLSI Strong Buy
- Analyst Count
- CNTX 3
- TLSI 5
- Target Price
- CNTX $6.83
- TLSI $12.10
- AVG Volume (30 Days)
- CNTX 210.1K
- TLSI 30.3K
- Earning Date
- CNTX 11-06-2024
- TLSI 11-14-2024
- Dividend Yield
- CNTX N/A
- TLSI N/A
- EPS Growth
- CNTX N/A
- TLSI N/A
- EPS
- CNTX N/A
- TLSI N/A
- Revenue
- CNTX N/A
- TLSI $26,892,000.00
- Revenue This Year
- CNTX N/A
- TLSI $61.76
- Revenue Next Year
- CNTX N/A
- TLSI $47.30
- P/E Ratio
- CNTX N/A
- TLSI N/A
- Revenue Growth
- CNTX N/A
- TLSI 67.92
- 52 Week Low
- CNTX $0.77
- TLSI $3.33
- 52 Week High
- CNTX $2.75
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- CNTX 25.94
- TLSI 55.44
- Support Level
- CNTX $1.56
- TLSI $3.74
- Resistance Level
- CNTX $2.32
- TLSI $4.50
- Average True Range (ATR)
- CNTX 0.16
- TLSI 0.34
- MACD
- CNTX -0.07
- TLSI 0.04
- Stochastic Oscillator
- CNTX 17.88
- TLSI 76.55
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.